Can FDG-PET/CT imaging be used to predict decline in quality of life in interstitial lung disease? A prospective study of the relationship between FDG uptake and quality of life in a UK outpatient setting.

Autor: Jordon LH; University of Cambridge, Cambridge, UK louise.jordon@nhs.net.; Department of Respiratory Medicine, Cambridge University Hospitals, Cambridge, UK., Ganeshan B; University College London Institute of Nuclear Medicine, London, UK., Nadeem I; Department of Respiratory Medicine, Cambridge University Hospitals, Cambridge, UK., Hoy L; University College London Institute of Nuclear Medicine, London, UK., Mahdi N; Department of Respiratory Medicine, Cambridge University Hospitals, Cambridge, UK., Porter JC; ILD Centre, University College London Hospital, London, UK.; Department of Respiratory Medicine, University College London, London, UK., Groves A; University College London Institute of Nuclear Medicine, London, UK., Win T; Department of Respiratory Medicine, Lister Hospital, Stevenage, UK.

Publikováno v: BMJ open [BMJ Open] 2024 May 30; Vol. 14 (5), pp. e081103. Date of Electronic Publication: 2024 May 30.

The HIF complex recruits the histone methyltransferase SET1B to activate specific hypoxia-inducible genes.

Autor: Ortmann BM; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Department of Medicine, University of Cambridge, Cambridge, UK., Burrows N; Cambridge Institute for Medical Research, The Keith Peters Building, Department of Medicine, University of Cambridge, Cambridge, UK., Lobb IT; Cambridge Institute for Medical Research, The Keith Peters Building, Department of Medicine, University of Cambridge, Cambridge, UK., Arnaiz E; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Department of Medicine, University of Cambridge, Cambridge, UK., Wit N; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Department of Medicine, University of Cambridge, Cambridge, UK., Bailey PSJ; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Department of Medicine, University of Cambridge, Cambridge, UK., Jordon LH; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Department of Medicine, University of Cambridge, Cambridge, UK., Lombardi O; NDM Research Building, University of Oxford, Headington, Oxford, UK., Peñalver A; Cambridge Institute for Medical Research, The Keith Peters Building, Department of Medicine, University of Cambridge, Cambridge, UK., McCaffrey J; Cambridge Institute for Medical Research, The Keith Peters Building, Department of Medicine, University of Cambridge, Cambridge, UK.; Department of Histopathology, Cambridge University NHS Foundation Trust, Cambridge, UK., Seear R; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Department of Medicine, University of Cambridge, Cambridge, UK., Mole DR; NDM Research Building, University of Oxford, Headington, Oxford, UK., Ratcliffe PJ; Ludwig Institute for Cancer Research, University of Oxford, Headington, Oxford, UK.; The Francis Crick Institute, London, UK., Maxwell PH; Cambridge Institute for Medical Research, The Keith Peters Building, Department of Medicine, University of Cambridge, Cambridge, UK., Nathan JA; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Department of Medicine, University of Cambridge, Cambridge, UK. jan33@cam.ac.uk.

Publikováno v: Nature genetics [Nat Genet] 2021 Jul; Vol. 53 (7), pp. 1022-1035. Date of Electronic Publication: 2021 Jun 21.